Sugi Predict

Sugi Predict / Compounds / SCHEMBL1547567

SCHEMBL1547567

SCHEMBL1547567

CCOc1c(Cl)cccc1Cl

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ L3MBTL1 Q9Y468 3/20 0.59
▸ KMT2A Q03164 4/20 0.52
▸ KDM4E B2RXH2 3/20 0.46
▸ MEN1 O00255 3/20 0.43
▸ RAB9A P51151 2/20 0.43
▸ NPC1 O15118 1/20 0.43
▸ HPGD P15428 3/20 0.42
▸ NQO1 P15559 1/20 0.42
▸ ALDH1A1 P00352 4/20 0.40
▸ LMNA P02545 2/20 0.40
▸ ABL1 P00519 1/20 0.40
▸ GAA P10253 1/20 0.40
▸ MAPT P10636 1/20 0.40
▸ RIN1 Q13671 1/20 0.40
▸ SMN1; SMN2 Q16637 1/20 0.40
▸ POLB P06746 1/20 0.39
▸ CYP3A4 P08684 2/20 0.39
▸ TP53 P04637 1/20 0.39
▸ CYP1A2 P05177 2/20 0.39
▸ CYP2D6 P10635 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3329675 0.87 L3MBTL1 (0.49) L3MBTL1KMT2AKDM4EMEN1RAB9A
SCHEMBL12129099 0.87 KDM4E (0.62) L3MBTL1KMT2AKDM4ERAB9AHPGD
SCHEMBL11336303 0.87 L3MBTL1 (0.49) L3MBTL1KMT2AKDM4EMEN1RAB9A
SCHEMBL2525928 0.87 L3MBTL1 (0.62) L3MBTL1KMT2AKDM4ERAB9AHPGD
SCHEMBL11494914 0.85 L3MBTL1 (0.47) L3MBTL1KMT2AKDM4EMEN1RAB9A
SCHEMBL18311257 0.85 L3MBTL1 (0.47) L3MBTL1KMT2AKDM4EMEN1RAB9A
SCHEMBL13490568 0.85 L3MBTL1 (0.47) L3MBTL1KMT2AKDM4EMEN1RAB9A
SCHEMBL26162638 0.85 L3MBTL1 (0.47) L3MBTL1KMT2AKDM4EMEN1RAB9A
SCHEMBL12129077 0.85 L3MBTL1 (0.47) L3MBTL1KMT2AKDM4EMEN1ALDH1A1
SCHEMBL3785150 0.85 ALDH1A1 (0.48) L3MBTL1KMT2AKDM4EMEN1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110372664-A Selective JAK2 inhibitor and its application 华东理工大学 2019-10-25 — — CN disclosed
CN-104650049-B Substituted pyridine compounds and its application method and purposes 广东东阳光药业有限公司 2018-06-08 — — CN disclosed
US-9669046-B2 Biodefenses using triazole-containing macrolides CEMPRA PHARMACEUTICALS, INC. (US) 2017-06-06 — — US disclosed
US-9439918-B2 Methods for treating gastrointestinal diseases CEMPRA PHARMACEUTICALS, INC. (US) 2016-09-13 — — US disclosed
EP-3031460-A1 BIODEFENSES USING TRIAZOLE-CONTAINING MACROLIDES Cempra Pharmaceuticals Inc. (US) 2016-06-15 — — EP disclosed
US-20160082028-A1 BIODEFENSES USING TRIAZOLE-CONTAINING MACROLIDES TETARD, INC. 2016-03-24 — — US disclosed
US-9273017-B2 (Thio)morpholine derivatives as S1P modulators ABBVIE BAHAMAS LIMITED (BS) 2016-03-01 — — US disclosed
US-9273017-B2 (Thio)morpholine derivatives as S1P modulators ABBVIE BAHAMAS LIMITED (BS) 2016-03-01 — — US disclosed
US-20150239857-A1 (THIO)MORPHOLINE DERIVATIVES AS S1P MODULATORS ABBVIE BAHAMAS LIMITED (BS) 2015-08-27 — — US disclosed
US-20150239857-A1 (THIO)MORPHOLINE DERIVATIVES AS S1P MODULATORS ABBVIE BAHAMAS LIMITED (BS) 2015-08-27 — — US disclosed
US-20100029648-A1 11-Beta HSD1 Inhibitors XIANG JASON SHAOYUN 2010-02-04 — — US disclosed
US-7632838-B2 11-beta HSD1 inhibitors WYETH (US) 2009-12-15 — — US disclosed
US-20090176980-A1 3-Substituted-6-Aryl Pyridines NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2009-07-09 — — US disclosed
CN-100441568-C Aminocyclohexyl ether compounds and uses thereof CARDIOME PHARMA CORP (CA) 2008-12-10 — — CN disclosed
CN-101282950-A Novel benzothiazolone derivatives ASTRAZENECA AB (SE) 2008-10-08 — — CN disclosed
US-7342115-B2 Binding antagonist and arylpyridine for antiinflammatory agents, cardiovascular disorders and antagonist or agonist and for immunology NEUROGEN CORPORATION (US) 2008-03-11 — — US disclosed
US-20070219198-A1 11-Beta HSD 1 inhibitors WYETH (US) 2007-09-20 — — US disclosed
US-7226950-B2 Sodium channel modulators THERAVANCE, INC. (US) 2007-06-05 — — US disclosed
CN-1780817-A Aminocyclohexyl ether compounds and uses thereof CARDIOME PHARMA CORP (CA) 2006-05-31 — — CN disclosed
US-4542243-A HALOALKYLATION, ETHERIFICATION, HYDRODEHALOGENATION, INSECTICIDES MITSUI TOATSU CHEMICALS, INC. (JP) 1985-09-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090176980-A1 3-Substituted-6-Aryl Pyridines C3AR1, C5AR1, C5AR2 L3MBTL1 3202/4885KMT2A 3960/4885KDM4E 2088/4885
US-20150239857-A1 (THIO)MORPHOLINE DERIVATIVES AS S1P MODULATORS S1PR3, S1PR1, S1PR2 L3MBTL1 1871/4885KMT2A 2005/4885KDM4E 716/4885
US-20100029648-A1 11-Beta HSD1 Inhibitors HSD11B1, HSD3B1, HSD11B2 L3MBTL1 1721/4885KMT2A 1609/4885KDM4E 1296/4885
US-20160082028-A1 BIODEFENSES USING TRIAZOLE-CONTAINING MACROLIDES ABHD16A, ABHD12, BRDT L3MBTL1 56/4885KMT2A 2568/4885KDM4E 3014/4885
US-20070219198-A1 11-Beta HSD 1 inhibitors HSD11B1, HSD11B2, HSD3B1 L3MBTL1 2300/4885KMT2A 1591/4885KDM4E 1360/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.